Barclays
ANTX icon

Barclays’s AN2 Therapeutics ANTX Stock Holding History

Barclays’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37K Buy
+400
New +$826 ﹤0.01% 4886
2024
Q2 		– Sell
-28,318
Closed -$92K – 4845
2024
Q1 		$92K Sell
28,318
-15,920
-36% -$173K ﹤0.01% 4461
2023
Q4 		$906K Buy
44,238
+41,068
+1,296% +$687K ﹤0.01% 3508
2023
Q3 		$51K Sell
3,170
-23,904
-88% -$271K ﹤0.01% 3860
2023
Q2 		$230K Sell
27,074
-5,699
-17% -$41K ﹤0.01% 3177
2023
Q1 		$323K Buy
32,773
+2,715
+9% +$30.2K ﹤0.01% 3536
2022
Q4 		$286K Buy
30,058
+2,780
+10% +$37.2K ﹤0.01% 3653
2022
Q3 		$475K Buy
27,278
+22,390
+458% +$261K ﹤0.01% 2734
2022
Q2 		$38K Sell
4,888
-13,332
-73% -$177K ﹤0.01% 4145
2022
Q1 		$275K Buy
+18,220
New +$276K ﹤0.01% 3241

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Barclays's ANTX Position: Q1 2026 in Review

Barclays opened a new position in AN2 Therapeutics (ANTX) in Q1 2026: 400 shares worth $1.37K. The stake represents ﹤0.01% of the portfolio and ranks #4886 among its holdings. This is a return to the name: Barclays previously reported a position in ANTX as recently as Q1 2024.

Barclays first reported a position in ANTX in Q1 2022 and has held it in 10 quarters since. The position peaked at $906K in Q4 2023. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Barclays held 400 shares of AN2 Therapeutics worth $1.37K as of Q1 2026.
  • AN2 Therapeutics was a new Barclays position in Q1 2026.
  • AN2 Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4886 holding.
  • Barclays first reported a position in AN2 Therapeutics in Q1 2022 and has held it in 10 quarters since.
  • Barclays's AN2 Therapeutics position peaked at $906K in Q4 2023.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.